ArticleThe Journal of antimicrobial chemotherapy2008
In vitro and in vivo antimicrobial activity of granulysin-derived peptides against Vibrio cholerae.
Article in The Journal of antimicrobial chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 20 citations in OpenAlex.
- Antibacterial and antibiofilm features ofHeliyon · 2024Article
- Going Beyond Host Defence Peptides: Horizons of Chemically Engineered Peptides for Multidrug-Resistant Bacteria.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2023Review
- Design of novel anti-quorum sensing peptides targeting LuxO to combatIn silico pharmacology · 2023Article
- Improved Purification of Human Granzyme A/B and Granulysin Using a Mammalian Expression System.Frontiers in immunology · 2022Article
- Gran1: A Granulysin-Derived Peptide with Potent Activity against IntracellularInternational journal of molecular sciences · 2021Article
- Vibrio cholerae LeuO Links the ToxR Regulon to Expression of Lipid A Remodeling Genes.Infection and immunity · 2016Article
- Human antimicrobial peptides and proteins.Pharmaceuticals (Basel, Switzerland) · 2014Article
- Principles of antidote pharmacology: an update on prophylaxis, post-exposure treatment recommendations and research initiatives for biological agents.British journal of pharmacology · 2010Review
- Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.The Journal of clinical investigation · 2009Article
- Biology and clinical relevance of granulysin.Tissue antigens · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectivesTo determine the antibacterial activity of synthetic peptides derived from the cationic antimicrobial peptide granulysin against Vibrio cholerae.
methodsThe antibacterial activity of granulysin-derived peptides was assessed in vitro by microtitre and cfu assays. Toxicity against human peripheral blood mononuclear cells (PBMCs) was measured by propidium iodide uptake and haemolysis by measuring the levels of haemoglobin released after incubation of red blood cells (RBCs) with granulysin peptides. The ability of granulysin peptides to control bacterial growth in vivo was tested by the treatment of suckling mice infected with V. cholerae with granulysin peptides, administered by gavage 1 h after infection and determining the number of bacteria in the small and large intestines 24 h after infection.
resultsAll peptides tested inhibited V. cholerae growth in vitro, and they were more effective against stationary phase cells. Two peptides, G12.21 and G14.15, effectively controlled bacterial growth in vivo. The peptides did not lyse RBCs and, with the exception of two peptides, exhibited very little toxicity against human PBMCs.
conclusionsThese results suggest that granulysin-derived peptides are candidates for the development of new agents for the treatment of V. cholerae infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.